BCL2L1 and breast carcinoma: We have recently demonstrated that in breast cancer, this “apoptosis-resistance” is underpinned in part by activation of a super-enhancer spanning the BCL2L1 locus, which increases intracellular levels of the anti-apoptotic Bcl-2 family protein Bcl-xL.